Transfemoral aortic stenosis treatments

INTRODUCTION

Since its introduction in 2002 11. Cribier A, Eltchaninioff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case. Circulation. 2002;106:3006-3008. Link, transcatheter aortic valve implantation (TAVI) has offered an alternative treatment for patients with severe symptomatic aortic stenosis (AS) who are poor candidates for traditional aortic valve replacement (AVR) due to their elevated mortality risk. TAVI is performed via a transfemoral, subclavian, transcarotid, transaortic or transapical approach. Feasibility trials have shown that TAVI can be performed in high, moderate and low risk individuals, safely and effectively, using the transfemoral (TF) approach 22. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet Lond Engl. 2015;385:2477-84. Link. After a significant learning curve, procedural success on the TF approach with the Edwards SAPIEN valve (Edwards Lifescience, Irvine, CA, USA) and the Commander™ catheter (Edwards Lifescience, Irvine, CA, USA) is 98%, with in-hospital mortality around 2.5% 1010. Auffret V, Lefevre T, Van Belle E, et al. Temporal Trends...